Close Menu

NEW YORK – Myriad Genetics on Monday announced plans to expand access to its myChoice CDx in Europe and China.

In China, Myriad signed a development and commercial agreement with Burning Rock Biotech to use its myChoice homologous recombination deficiency (HRD) test in Phase III drug development studies and in clinics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.